View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
March 10, 2022

Thermo Fisher introduces two RT-LAMP tests to detect viral pathogens

The solutions are intended to help public health professionals by providing low-cost options for detecting viral pathogens.

Thermo Fisher Scientific has introduced two new reverse transcription loop-mediated isothermal amplification (RT-LAMP)-based solutions to simplify surveillance of viral pathogens, including SARS-CoV-2.

The new solutions, Invitrogen Colorimetric ReadiLAMP kit, SARS-CoV-2, and Invitrogen SuperScript IV RT-LAMP Master Mix, are also designed to support active research of viral pathogens.

The isothermal RT-LAMP-based kits are intended to help global public health professionals by providing quick and low-cost options for detecting viral pathogens.

Thermo Fisher Scientific molecular biology vice-president and general manager Dale Patterson said: “In the global fight against Covid-19 and future infectious disease outbreaks, researchers need cost-effective, easy-to-use solutions for rapid detection of viral pathogens.

“With RT-LAMP technology, researchers can accurately detect the presence of a pathogen by seeing a simple colour change with the naked eye.

“Our new solutions enable frequent – even daily – surveillance, without complex instrumentation or highly trained staff, making them ideal tools to support community surveillance in resource-constrained areas.”

The off-the-shelf assay Invitrogen Colorimetric ReadiLAMP Kit, SARS-CoV-2, uses a LAMP-based solution for the detection of SARS-CoV-2 from nasal, saliva or nasopharyngeal swab samples.

It has two protocols. One is a rapid, 30-minute turnaround time for crude sample types, and the other is a one-hour turnaround time for purified RNA sample types.

Thermo Fisher’s Invitrogen SuperScript IV RT-LAMP Master Mix kit has been developed to help researchers seeking to develop or research their own assays for various applications.

It provides quick detection of viral pathogens, including influenza, measles and SARS-CoV-2, within five minutes.

The company stated that the optimised master mix is compatible with several methods and offers flexibility for optimised assay development for a range of RNA and DNA targets and concentrations.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Medical Device Network